work.|Conditional recommendation based on very-low-quality evidence; may consider switching to an IL-12/23i biologic and MTX combination therapy if the patient had had a partial response to the existing regimen or in patients with concomitant uveitis, as uveitis may respond to MTX therapy. Continuing MTX during the transition to an IL-12/23i biologic was discussed as potentially beneficial to allow the new therapy time to work.|</p>